The AMP Parkinson’s Disease and Related Disorders concept proposes to build on the infrastructure established during AMP Parkinson’s Disease, leveraging these resources to drive clinical and molecular characterization of a broader range of Parkinson patients, as well as other a-synucleinopathies.
Parkinson’s Disease (PD) is a chronic and progressive neurological disease characterized by resting tremor, muscle rigidity, slowness of movement, impaired balance, and a shuffling gait. People with PD also develop non-motor symptoms, such as behavioral changes and cognitive impairment. In the United States alone, it is estimated that more than 1 million people live with PD and approximately 90,000 Americans are diagnosed with the disease each year.
The first phase of the AMP PD project was established to address the absence of disease-modifying therapies for people living with PD and to streamline data consolidation from diverse natural history studies, each with their access pathway to advance the discovery and development of therapeutics for PD.
The proposed second phase, AMP Parkinson’s Disease and Related Disorders (AMP PDRD) seeks to employ a data-driven approach to identify and validate biomarkers distinguishing Parkinson’s disease from Parkinsonism, aiming to enhance the clinical trial success and ultimately broaden treatment options for individuals affected by these conditions.
The AMP PDRD design phase started March, 2023